Sorafenib: targeting multiple tyrosine kinases in cancer.

  • Jens Hasskarl
  • Published 2014 in
    Recent results in cancer research. Fortschritte…


Sorafenib (BAY 43-9006, Nexavar®) is an oral multiple tyrosine kinase inhibitor. Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the Raf-Ras pathway, vascular endothelial growth factor (VEGF) pathway, and FMS-like tyrosine kinase 3 (FLT3). Sorafenib was approved by the FDA in fast track for advanced renal cell… (More)
DOI: 10.1007/978-3-642-54490-3_8


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.


Citations per Year

Citation Velocity: 6

Averaging 6 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.